The medication operates as a dual-agonist, targeting both GLP-1 and GIP hormone pathways, which are instrumental in regulating appetite and insulin secretion
The team said previous research had highlighted the risk of gastrointestinal issues in patients with diabetes, but theirs is the first large, population-level study to explore the likelihood of it happening in non-diabetic people
Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, stated, Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH. He noted that this approval complements the proven weight loss, cardiovascular benefits, and broader evidence linked to semaglutide
I can say this does not help bloating at all
Second Nature members on semaglutide lost an average of 17.1% over 12 months 5
Importantly, this process respects the bodys natural feedback mechanisms somatostatin, the hormone that inhibits GH release, continues to function normally